Stoke Therapeutics is a biotechnology company focused on treating the underlying causes of severe genetic diseases by upregulating protein expression. Co. is developing antisense oligonucleotide, medicines that target ribonucleic acid (RNA), and modulate precursor-messenger RNA, splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. Co. designed its primary product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epile. The STOK stock yearly return is shown above.
The yearly return on the STOK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the STOK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|